Skip to main content

Mercury Poisoning

3
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

EmeraMed
EmeraMedIreland - Dublin
2 programs
1
1
NBMI Treatment in Patients With Mercury ToxicityPhase 2/31 trial
EmeramidePhase 21 trial
Active Trials
NCT02486289Completed36Est. Apr 2016
NCT04183595Unknown116Est. Nov 2024
AB Science
AB ScienceFrance - Paris
1 program
1
emeramidePhase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EmeraMedNBMI Treatment in Patients With Mercury Toxicity
EmeraMedEmeramide

Clinical Trials (2)

Total enrollment: 152 patients across 2 trials

NCT04183595EmeraMedNBMI Treatment in Patients With Mercury Toxicity

NBMI Treatment in Patients With Mercury Toxicity

Start: Nov 2023Est. completion: Nov 2024116 patients
Phase 2/3Unknown

Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

Start: Aug 2015Est. completion: Apr 201636 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.